UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $691.34 Million Stock Position in DexCom, Inc. $DXCM

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 22.6% during the first quarter, HoldingsChannel reports. The firm owned 10,123,525 shares of the medical device company’s stock after buying an additional 1,868,241 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC’s holdings in DexCom were worth $691,336,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of DXCM. Golden State Wealth Management LLC boosted its stake in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom in the first quarter valued at about $27,000. Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter valued at about $38,000. Alpine Bank Wealth Management purchased a new stake in shares of DexCom in the first quarter valued at about $40,000. Finally, Private Trust Co. NA increased its holdings in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after buying an additional 335 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In other news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. This represents a 9.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $88.99, for a total transaction of $130,459.34. Following the completion of the transaction, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,855 shares of company stock worth $1,477,344. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DXCM shares. Piper Sandler raised their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Barclays lifted their target price on shares of DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. Morgan Stanley lifted their price target on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $99.89.

DexCom Stock Performance

Shares of DexCom stock opened at $78.40 on Wednesday. The stock has a market cap of $30.74 billion, a price-to-earnings ratio of 54.44, a PEG ratio of 1.64 and a beta of 1.48. The firm’s 50-day moving average is $81.29 and its 200 day moving average is $78.92. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.